key: cord-1035811-jvenua7z authors: O’Donovan, Sinead M; Eby, Hunter; Henkel, Nicholas D; Creeden, Justin; Imami, Ali; Asah, Sophie; Zhang, Xiaolu; Wu, Xiaojun; Alnafisah, Rawan; Taylor, R. Travis; Reigle, James; Thorman, Alexander; Shamsaei, Behrouz; Meller, Jarek; McCullumsmith, Robert E title: Identification of new drug treatments to combat COVID19: A signature-based approach using iLINCS date: 2020-04-30 journal: Res Sq DOI: 10.21203/rs.3.rs-25643/v1 sha: 74cc85d081da2286c5a4e27f7eb5dadb4575519c doc_id: 1035811 cord_uid: jvenua7z The COVID-19 pandemic caused by the novel SARS-CoV-2 is more contagious than other coronaviruses and has higher rates of mortality than influenza. As no vaccine or drugs are currently approved to specifically treat COVID-19, identification of effective therapeutics is crucial to treat the afflicted and limit disease spread. We deployed a bioinformatics workflow to identify candidate drugs for the treatment of COVID-19. Using an “omics” repository, the Library of Integrated Network-Based Cellular Signatures (LINCS), we simultaneously probed transcriptomic signatures of putative COVID-19 drugs and signatures of coronavirus-infected cell lines to identify therapeutics with concordant signatures and discordant signatures, respectively. Our findings include three FDA approved drugs that have established antiviral activity, including protein kinase inhibitors, providing a promising new category of candidates for COVID-19 interventions. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the first global pandemic in a decade, coronavirus disease 2019 (COVID-19)1. Initial reports of a novel SARS-like acute respiratory syndrome emerged in late 2019 from Wuhan, China2. Since then, COVID-19 has spread to over 150 countries and all continents except Antarctica3,4. At the time of writing, over one million people have been infected, over 60,000 deaths have been attributed to this outbreak4, and millions of additional infections are projected to occur globally in upcoming months3,4. COVID-19 is less infectious than SARS-CoV1 but more lethal than the common flu1 with an estimated mortality rate of 3.4%2. The incubation period, on average, is 5.2 days; in severe cases, the median time course from disease onset to death is 14 days5. While fever, cough, fatigue, and myalgias6-10 are common, mild presentations of COVID-19, the disease can fatally evolve into a severe pneumonia, complicated by acute respiratory distress syndrome, hypoxemic respiratory failure, and cytokine storm secondary to prolonged infection8. In addition to the significant medical burden imposed by this outbreak, it is estimated that the global economic cost of COVID-19 will be over $1 trillion in 202011. The emotional toll on individuals will be incalculable, with prolonged quarantine policies restricting personal freedom and social contacts. Current treatment is supportive and is focused on managing disease complications and secondary symptoms12-14. Drugs indicated for other infectious diseases, such as antiviral and antiparasitic therapies, have been used for COVID-19 patients, but there is a paucity of evidence supporting their efficacy15. There is now an immediate need to identify therapeutic compounds that can be rapidly repurposed for COVID-19 treatment. Recent efforts to address this pressing public health concern include a comprehensive network-based approach to identify 16 candidate drugs (and drug combinations) that may be repurposed for the treatment of this disease16. To further expand this area of novel research, in the present study we employ a bioinformatics approach with the goal of datamining an extensive drug signature resource to distill a list of drug therapies that may prove fruitful in the search for COVID-19 therapies. To accomplish this, we apply a signature-based connectivity analysis17-19 utilizing the extensive chemical perturbagen "omics" datasets deposited in the Library of Integrated Network-based Signatures (LINCS) database17,20,21. LINCS is a repository for systematically generated gene signatures based on the L1000 assay22. These gene signatures reflect cellular perturbations in response to pharmacological treatments; LINCS contains datasets for over 40,000 small molecules (drugs) in various cell lines. Different small molecules that produce signatures composed of highly similar patterns of gene expression changes, or "concordant" signatures, reflect shared connections between small molecules. Here, we apply a two-pronged approach to identify novel compounds for the treatment of COVID-19. First, we identify pharmacologic therapies that are effective in the treatment of pathogens in the coronavirus family, like SARS and Middle East Respiratory Syndrome (MERS), as well as other viral illnesses23-27. We then generate gene signatures for these targets in iLINCS (http://ilincs.com) and highlight connected small molecule signatures to identify which of these candidate drugs are highly concordant with current therapies. Simultaneously, we generate gene signatures from coronavirus infected human cell line transcriptomic datasets. We analyze these data in iLINCS to directly match disease signatures with discordant small molecule signatures, thereby identifying drugs that "reverse" the disease signature. Finally, we compile a list of drugs from these two approaches to identify high-yield candidate drugs that may have therapeutic utility in the treatment of COVID-19. Applying the workflow outlined in Figure 1 , we identified nine drugs, with known efficacy in treating coronavirus family pathogens, for which there are gene signatures in iLINCS (Table 1 and extended information in Table S1 ). These drugs were clustered into five groupings according to their mechanism of action, Anatomical Therapeutic Chemical (ATC) classification and/or structural similarity (Table 1) . Simultaneously, we extracted differential gene expression data on the 978 genes that comprise the L1000 from a publically available SARS (GSE56192) transcriptomic dataset. Gene signatures composed of genes changed LFC ≥ 0.5 and ≤ -0.5 were generated for the disease signature (Table S2 ). In iLINCS, we conducted connectivity analysis to identify chemical perturbagens that are highly concordant to the drug target groupings (≥ 0.321) or highly discordant to the disease signatures (≤ -0.321), established minimum iLINCS concordance score cutoffs 22,28. This resulted in identification of 112 chemical perturbagens common to two cell lines, MCF7 and HA1E ( Figure 2 ). Fourteen chemical perturbagens were identified at concordance scores ≥ 0.8 in both cell lines and were considered "candidate" drugs for the treatment of COVID-19 ( Table 2 ). The Tanimoto scores for the candidate drugs and the original 9 drug targets were generated, showing structural similarity between drugs currently in use for the treatment of coronavirus family pathogens and our newly identified candidate drugs ( Figure S1 ). Unsupervised clustering of L1000 disease gene signatures demonstrates significant differences in patterns of gene expression induced by SARS, MERS and influenza ( Figure S2 ). Influenza is utilized as a control dataset as it represents a non-coronavirus pathogen that also causes respiratory illness. As promising, Genistein has yet to be explored as an antiviral therapy in humans. AT9283 is a broad protein kinase inhibitor55,56. Canonically, it acts as a receptor and nonreceptor tyrosine kinase inhibitor but also effectively inhibits serine/threonine kinases, Aurora A/B kinases, Janus kinases (JAK) 2/3, and ABL kinases57. In a clinical setting, AT9283 has been predominantly studied as an antineoplastic for hematologic malignances and several trials are underway58-60. AT9283 has not been explored directly as an antiviral, although the ABL kinase inhibitor, Imatinib, is efficacious in preventing coronavirus (SARS-CoV and MERS-CoV) viral fusion with endosomes, effectively halting viral activity61. Given its role as a broad-spectrum kinase inhibitor, researching the antiviral properties of AT9283 may prove fruitful. Serine Threonine Kinase Inhibitors. Alvocidib (also known as flavopiridol) is a pan-specific cyclindependent kinases (CDK) inhibitor that inhibits CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, and CDK962. Alvocidib is under clinical investigation as an antineoplastic for both solid tumors and hematologic malignancies63. Like other CDK kinase inhibitors, Alvocidib has been implicated as a broad antiviral against several DNA virus families64. Alvocidib has been studied as an inhibitor of transcriptional activation and elongation in the infectious lifecycle of DNA viruses (HSV-1, HSV-2) and retroviruses (HIV)29-32 and also suppresses replication of Influenza A33. This suggests that Alvocidib is a strong candidate drug for repurposing. The antiviral activity of the following serine/threonine kinase candidate drugs have yet to be studied directly and further research is required to determine their potential as repurposable antiviral therapies. However, these candidates are members of drug families with demonstrated antiviral or antimicrobial properties that could be exploited for the treatment of COVID-19. GSK-1059615 is a reversible, ATP-competitive, thiazolidinedione inhibitor of phosphoinositide 3-kinase (PI3K) and has been studied as an antineoplastic for solid tumors65. Though the antiviral activity of GSK-1059615 has yet to be determined, the thiazolidinedione drug family has a broad range of antibacterial and antiparasitic activity66-68. Idelalisib is a phosphoinositol 3-kinase ( Idebenone is a synthetic derivative of ubiquinone, also known as Coenzyme Q1082,83. This drug acts to increase the production of ATP by enhancing oxidative phosphorylation. As a general antioxidant, Idebenone may prevent lipid peroxidation, reduce membrane oxidative stress, and scavenge free radicals84. Idebenone has been used for a number of human neurodegenerative disorders, and its safety has been validated85,86. Antioxidants such as Idebenone have been hypothesized to mitigate the deleterious effects of a "reactive-oxygen species burst"45 from viruses with a pulmonary and respiratory predilections (Influenza and SARS)44. However, further work is required to determine the utility of antioxidants like Idebenone as adjunct treatments for COVID-19. Penicillin V is a beta-lactam antibiotic and is indicated primarily for treating gram- The COVID-19 outbreak is an escalating public health concern that requires a swift and Baricitinib may reduce the ability of the virus to enter cells and is currently in clinical use as a treatment for rheumatoid arthritis. To advance therapeutic discovery and the identification of candidate drugs for COVID-19, we employ an alternative, signature-based bioinformatic approach. In this study, we data mine the extensive LINCS database, which acts as a repository of "L1000" gene signatures generated by treating various cell lines with over 20,000 small molecules. The L1000 genes are a reduced representation of the transcriptome, a method by which a select group of genes account for ~82% of the information content of the transcriptome95. The approach involved feature selection/reduction techniques applied to 12,063 gene expression samples profiled on microarrays from GEO96. Benchmarking of the L1000 assay versus RNAseq yielded a cross-platform correlation of 0.8495, suggesting the L1000 assay represents an efficient alternative to RNA-Seq. Utilizing this resource, our two-pronged connectivity analysis approach identified candidate drugs that are 1) highly concordant to current drugs employed to treat coronavirus family pathogens and 2) highly discordant to SARS disease gene signatures. Interestingly, the antibiotic quinacrine was also identified in a recent network-based COVID-19 drug screen16 and another β-lactam antibody ceftriaxone, is in clinical trial for (adjunct) treatment of COVID-19 (NCT02735707). The immunosuppressant Sirolimus was identified in our study, albeit at a less stringent threshold, as well as in another in silico drug screen16, as a candidate repurposable drug for treating COVID19. Immunosuppressants may address the symptoms resulting from overactivation of the immune system ("cytokine storm") in response to COVID-19 infection114, and this class of drug is also in clinical trial as adjunct treatments (e.g. Thalidomide NCT04273529). The antimicrobial drugs that comprise our drug target groupings are limited to those that have gene signatures in iLINCS. We analyze gene signatures generated in two cell lines, MCF7 and HA1E, as data was available for all of our drug targets in these cell lines only. The workflow for this study is outlined in Figure 1 . We conducted a PubMed search using search terms "coronavirus" or "COVID-19" and "antiviral" or "drug" or "therapy" and generated a list of compounds utilized to treat coronavirus family pathogens or identified as putative COVID-19 therapeutics. We identified seventeen drugs for potential analysis (Table S1 ). L1000 gene signature datasets were available for nine of the seventeen drugs (Table 1) Next, we grouped the nine drug targets based on canonical mechanism of action, the Anatomical Therapeutic Chemical (ATC) classification, and structural similarity. Drugs were grouped together if they were categorized by at least two of the three methods. The database DrugBank (https://www.drugbank.ca/) was used to group the drugs by their canonical mechanisms of actions. Drug identification was only referenced from Drug Bank I.D. If no Drug Bank I.D. was available, this is indicated in Table 1 and Table S1 . If there was no listed MOA from Drug Bank, then the MOA was appropriately cited, referenced from iLINCS, or was referenced from Gene Ontology (GO) Molecular Function 2018 accessed via Enrichr (http://amp.pharm.mssm.edu/Enrichr/enrich). Next, drugs were classified based on the ATC classification system (https://www.whocc.no/atc_ddd_index/). If a particular drug did not have an ATC classification, it was marked as "unclassified." From DrugBank, we also collected the clinical indications, gene targets, and trade names. In addition, we probed the ATC Index (https://www.whocc.no/atc_ddd_index/) to identify the first-and second-level of drug classifications. The first-level classification was used to confirm drug grouping. Finally, to group drugs based on structural similarity, the structural data files (sdf) for the nine drugs under investigation were downloaded from DrugBank. The package ChemmineR was used to generate 1024-bit binary fingerprints for each compound. The Tanimoto coefficient between all pairs of fingerprints were then computed also using the R package "ChemmineR". The Tanimoto coefficient, also known as the Jaccard similarity, represents the most popular measure for chemical similarity115 and is the ratio of the intersection of the two fingerprints divided by the union of the two fingerprints. The data were visualized using the "Corrplot" package. With a final list of drug clusters, the individual drug signatures within each grouping were collected and averaged across the L1000. Using the iLINCS portal, we acquired the LINCS chemical perturbagen signatures (978 genes that comprise the L1000) for each drug candidate. Genes with a log fold change (LFC) value of ≥ 0.85 or ≤ -0.85, indicating differential gene expression induced by the drug target compared to a corresponding control cell line, were exported to Microsoft Excel. Gene lists were pooled and averaged such that a master list of differentially expressed genes was generated for each drug candidate family. For example, genes with a LFC ≥ 0.85 or ≤ -0.85 that appeared in both the hydroxychloroquine gene signature and the chloroquine gene signature were averaged to calculate mean values for each differentially expressed gene in drug target grouping 1. Next, the upregulated genes (LFC ≥ 0.85) were clustered and the downregulated genes (≤ -0.85) were clustered. These clusters were uploaded as user generated signatures into iLINCS. Next, we identified connected chemical perturbagens, utilizing a concordance threshold score of ≥ 0.321, an established minimum concordance score cutoff 22,28, to identify chemical perturbagen signatures that are considered highly correlated with our drug target grouping signatures. selected for these datasets is 24h. We conducted differential gene expression analysis of these datasets comparing virus infected samples to corresponding control samples. RNAseq raw count data were analyzed using edgeR R package v.3.28.1 for differential gene expression118. As a quality control step, we require that a gene have a count of at least 10 in at least some libraries before it is considered to be expressed. Normalization was performed using the default method, trimmed mean of M-values (TMM). This step is performed by using the calcNormFactor function, which returns the DGEList argument with a set of calculated normalization factors, one for each sample, to eliminate composition biases between libraries. org.Hs.eg.db R package v.3.10.0 was used to complement the gene annotation. Following analysis of the disease transcriptomic datasets, the subset of genes that comprise the LINCS L1000 were extracted from the differentially expressed gene list for each dataset. When the L1000 genes were extracted from the SARS and MERS RNAseq datasets, 944 and 947 overlapping genes, respectively, were extracted. We used the existing gene raw counts from GEO and did not remap the genes. Thus, if some of the L1000 genes were not mapped we were unable to access their expression. In addition, we applied a gene raw count cutoff of 10 as a quality control step, which also reduced the number of L1000 genes found in the final differential expression gene lists. The extracted L1000 genes were uploaded into iLINCS. Genes with LFC in expression within three thresholds, 0.26 LFC, 0.5 LFC and all L1000 genes, were identified with a custom R script for further processing. As described above, upregulated and down regulated disease gene signatures were generated for each disease dataset (within each threshold) and uploaded into iLINCS to identify connected perturbagens. For disease gene signatures, chemical perturbagen signatures that are highly discordant (discordance score ≤ -0.321), indicating these perturbagens may "reverse" the disease signature, were identified. Genes at LFC ≥ 0.5 and ≤ -0.5 threshold were then carried forward for further analysis. Utilizing this gene threshold generated optimal SARS disease signatures to identify a large number of discordant chemical perturbagens. In addition, we identified a microarray dataset of human airway epithelium cells infected with influenza A of the H1N1 serotype (GSE47963, 36h time point). The microarray data were extracted using GEOquery R package v.2.54.1 119. Specifically, SOFT format files from GEO containing all of the information in the GEO records were parsed. The normalized gene expression values associated with SOFT files for selected samples filewere then analyzed using limma R package v.3.42.2, linear model for microarray120. As described above, the L1000 genes were extracted. Since this dataset was performed on the microarray platform, which limits the gene detection to the probes available in the arrays, we extracted 968 L1000 genes. In addition to the MERS dataset, which represents a pathogenic coronavirus like SARS, the influenza dataset was used as a comparison dataset in unsupervised clustering and biological pathway analyses (described below). Influenza A represents a non-corona family virus that also causes respiratory disease121. A total of 906 overlapping L1000 genes were used in clustering analysis and heat map generation. Candidate drugs were identified from the chemical perturbagen connectivity analysis using a custom script in R. The script downloaded the data from the iLINCS API and used the following criteria: Chemical perturbagens had a concordance score ≥ 0.321 compared to drug target grouping signatures or a discordance score ≤ -0.321 compared to disease signatures in cell lines MCF7 In total, 112 chemical perturbagens were common to both cell lines. Chemical perturbagens with concordance scores ≥ 0.8 in the MCF7 AND HA1E cell lines are considered "candidate drugs," resulting in a final list of 14 candidate drugs. Heat maps of the L1000 gene data for each of the drug target groupings, candidate drugs and disease (SARS and MERS) datasets were generated as described above. In addition, the L1000 gene data for Furosemide (FUR), a drug which is not used to treat viral pathogens or related illnesses, and influenza, a non-coronavirus family pathogen associated with respiratory illness, were included in the heat maps. These datasets acts as controls, suggesting that the drug target groupings and candidate drugs, but not unrelated drugs, are discordant with coronavirus disease signatures specifically. The sdf for the 9 drugs that comprise the drug target groupings were downloaded from DrugBank. The sdf files for the 14 candidate drugs were downloaded from PubChem and Chembl. ChemmineR was used to convert the sdf files to binary chemical fingerprints. The Tanimoto coefficients of the chemical fingerprints between the 9 drugs that comprise the drug target groupings and the 14 candidate drugs for all pairs were computed using the ChemmineR library. The Tanimoto coefficient, also known as the Jaccard similarity, represents the established measure for chemical similarity. The data were then visualized as a heat map using the "gplots" package. R scripts utilized in data processing can be accessed at https://github.com/AliSajid/Covid19. Unsupervised clustering analysis was performed on log fold change values of disease and drug target signatures and heat map was generated using "pheatmap" package122 in R programming language. To generate biological pathways associated with the drug targets and disease datasets, the gene list This is a list of supplementary files associated with this preprint. Click to download. Supplementalmaterial.pdf Naming the coronavirus disease (COVID-19) and the virus that causes it Report of the WHO-China Joint Mission on Coronavirus Disease Rolling updates on coronavirus disease (COVID-19) Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan Clinical features of patients infected with 2019 novel coronavirus in Wuhan Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study Clinical Characteristics of Coronavirus Disease 2019 in China T.a. Coronavirus (COVID-19): New, analysis and resources Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 Representing, storing and accessing molecular interaction data: a review of models and tools The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease Extraction and analysis of signatures from the Gene Expression Omnibus by the crowd The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations Connecting omics signatures of diseases, drugs, and mechanisms of actions with iLINCS A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019:a retrospective cohort study A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Random-set methods identify distinct aspects of the enrichment signal in gene-set analysis Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large Drugs to cure avian influenza infection--multiple ways to prevent cell Modulation of Oxidative Stress: Pharmaceutical and Pharmacological Aspects GSK-3-selective inhibitors derived from Tyrian purple indirubins Receptor tyrosine kinase inhibitors block multiple steps of influenza a virus replication Physiological and morphological effects of genistein against the liver fluke, Fasciola hepatica Topoisomerase poisoning by genistein in the intestine of Genistein in Sanfilippo disease: a randomized controlled crossover trial A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients Epstein-Barr virus (EBV) latent membrane protein 2A regulates B-cell receptor-induced apoptosis and EBV reactivation through tyrosine phosphorylation Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion Five years of progress on cyclindependent kinases and other cellular proteins as potential targets for antiviral drugs CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses Pyridin-4-yl)quinolin-6-yl)methylene)thiazolidine-2,4-dione Synthesis of pyrazole encompassing 2-pyridone derivatives as antibacterial agents Design, synthesis and biological characterization of thiazolidin-4-one derivatives as promising inhibitors of Toxoplasma gondii Novel 2-thioxothiazolidin-4-one inhibitors of bacterial MurD ligase targeting D-Glu-and diphosphate-binding sites Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis Macrofilaricidal Efficacy of Repeated Doses of Ivermectin for the Treatment of River Blindness Control, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa Ivermectin -Old Drug, New Tricks? wonder drug' from Japan: the human use perspective The pharmacokinetics and interactions of ivermectin in humans--a mini-review Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin Antiparasitic drugs Eosinophilia in patients infected with human immunodeficiency virus Idebenone: an emerging therapy for Friedreich ataxia Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier? A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders Idebenone: Novel Strategies to Improve Its Systemic and Local Efficacy Onset of penicillin rashes: relation between type of penicillin administered and type of immune reactivity Clinical practice. Antibiotic allergy Baricitinib as potential treatment for 2019-nCoV acute respiratory disease COVID-19: combining antiviral and anti-inflammatory Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles Gene Expression Omnibus: NCBI gene expression and hybridization array data repository FDA-approved small-molecule kinase Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication. Assay and drug development technologies Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals Influenza Virus Infections and Cellular Kinases Glycogen synthase kinase-3 regulates the phosphorylation of severe acute respiratory syndrome coronavirus nucleocapsid protein and viral replication Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1 Palbociclib, a selective inhibitor of cyclin-dependent kinase4/6, blocks HIV-1 reverse transcription through the control of sterile alpha motif and HD domain-containing protein-1 (SAMHD1) activity Combination of Leflunomide and Everolimus for treatment of BK virus nephropathy Inhibition of human immunodeficiency virus type-1 by cdk inhibitors Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection Efficacy and Safety of Ivermectin against Dengue Infection: A Phase III, Randomized, Double-blind, Placebo-controlled Trial. in The 34th Annual Meeting The Royal College of Physicians of Thailand 'Internal Medicine and One Health Ivermectin: a promising anti-dengue replication treatment [abstract S634 Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro Oxidants and antioxidants in viral diseases: disease mechanisms and metabolic regulation Preventing and treating secondary bacterial infections with antiviral agents COVID-19: consider cytokine storm syndromes and immunosuppression Molecular similarity in medicinal chemistry Severe acute respiratory syndrome vs. the Middle East respiratory syndrome Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. The new england journal o f medicine From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasilikelihood pipeline GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor Limma: linear models for microarray data Towards a sane and rational approach to management of Influenza H1N1 2009 Pretty Heatmaps Overview of the workflow to identify candidate repurposable drugs to combat COVID-19. A) Acknowledgements: This work was supported by NIMH R01 MH107487 and MH121102.